摘要
嵌合抗原受体(CAR)T细胞技术是利用抗原-抗体或配体-受体间的特异性以及高亲和力为介导,从而提高T淋巴细胞对靶细胞/肿瘤细胞的识别与杀伤能力的一种抗肿瘤免疫疗法。这种抗肿瘤疗法不受MHC限制、靶向性强、疗效持久,因而发展迅速。目前,在血液肿瘤治疗方面已获得了令人瞩目的成就,在实体瘤领域也前景广阔,令人期待。但事无完美,CAR-T疗法目前仍存在亟待解决的问题,比如细胞因子释放综合征、脱靶毒性等安全问题。本文将对其临床治疗的优势、安全性、发展面临的挑战等做出分析和探讨。
The chimeric antigen receptor(CAR)T cell technology is an approach of anti-tumor immunotherapy,which is mediated by antigen and antibody or ligand and receptor in a manner of high specificity and high affinity,thereby enhancing the recognition and killing ability of the T lymphocytes to the target cells/tumor cells.This kind of anti-tumor therapeutic approach has been rapidly developed because of its some advantages,including MHC independent,strong targeting,long-lasting effect.To date,it has created a remarkable achievement in the treatment of hematological tumors,and simultaneously it also presented a promising anticancer activity in solid tumors.However,There are still some problems which have restrained CAR-T therapeutic outcome in clinical trials,such as cytokine release syndrome,off-target toxicity and other safety issues.In this review,we will summarize and discuss its advantages,safety and development challenges in clinical trials.
作者
张宸瑜
陈柯远
贾雨婷
季少平(指导)
ZHANG Chen-Yu;CHEN Ke-Yuan;JIA Yu-Ting;JI Shao-Ping(Henan University School of Basic Medical Sciences,Kaifeng 475000,China)
出处
《中国免疫学杂志》
CAS
CSCD
北大核心
2020年第22期2791-2796,2801,共7页
Chinese Journal of Immunology
基金
国家自然科学基金(No.31371386)。
